Literature DB >> 29342300

Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.

Jemima Albayda1, Clifton O Bingham1, Ami A Shah1, Ronan J Kelly2, Laura Cappelli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29342300      PMCID： PMC6251606          DOI： 10.1093/rheumatology/kex470

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  7 in total

1.  Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment.

Authors:  Laura C Cappelli; Jarushka Naidoo; Clifton O Bingham; Ami A Shah
Journal:  Immunotherapy       Date:  2017-01       Impact factor: 4.196

2.  Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.

Authors:  Laura C Cappelli; Anna Kristina Gutierrez; Alan N Baer; Jemima Albayda; Rebecca L Manno; Uzma Haque; Evan J Lipson; Karen B Bleich; Ami A Shah; Jarushka Naidoo; Julie R Brahmer; Dung Le; Clifton O Bingham
Journal:  Ann Rheum Dis       Date:  2016-06-15       Impact factor: 19.103

3.  Lytic bone lesions suspected for metastasis: ultrasonically guided fine-needle aspiration biopsy.

Authors:  G Civardi; T Livraghi; P Colombo; F Fornari; L Cavanna; L Buscarini
Journal:  J Clin Ultrasound       Date:  1994-06       Impact factor: 0.910

4.  Musculoskeletal ultrasound including definitions for ultrasonographic pathology.

Authors:  Richard J Wakefield; Peter V Balint; Marcin Szkudlarek; Emilio Filippucci; Marina Backhaus; Maria-Antonietta D'Agostino; Esperanza Naredo Sanchez; Annamaria Iagnocco; Wolfgang A Schmidt; George A W Bruyn; George Bruyn; David Kane; Philip J O'Connor; Bernhard Manger; Fred Joshua; Juhani Koski; Walter Grassi; Marissa N D Lassere; Nanno Swen; Franz Kainberger; Andrea Klauser; Mikkel Ostergaard; Andrew K Brown; Klaus P Machold; Philip G Conaghan
Journal:  J Rheumatol       Date:  2005-12       Impact factor: 4.666

5.  Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.

Authors:  Matthew M K Chan; Richard F Kefford; Matteo Carlino; Arthur Clements; Nicholas Manolios
Journal:  J Immunother       Date:  2015-01       Impact factor: 4.456

Review 6.  Toxicities of Immunotherapy for the Practitioner.

Authors:  Jeffrey S Weber; James C Yang; Michael B Atkins; Mary L Disis
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

7.  Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.

Authors:  C Calabrese; E Kirchner; A Kontzias; V Velcheti; L H Calabrese
Journal:  RMD Open       Date:  2017-03-20
  7 in total
  7 in total

Review 1.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

Review 2.  Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.

Authors:  Laura C Cappelli; Clifton O Bingham
Journal:  Arthritis Rheumatol       Date:  2021-03-05       Impact factor: 10.995

3.  Sonographic Findings in Inflammatory Arthritis Secondary to Immune Checkpoint Inhibition: A Case Series.

Authors:  Jemima Albayda; Eric Dein; Ami A Shah; Clifton O Bingham; Laura Cappelli
Journal:  ACR Open Rheumatol       Date:  2019-06-12

4.  Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.

Authors:  Marie Kostine; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

5.  Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.

Authors:  Kazuya Abe; Yuichi Ishikawa; Michio Fujiwara; Hiroko Yukawa; Takeshi Yanagihara; Saori Takei; Hitoshi Arioka; Yasuhiko Kita
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817

Review 6.  Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe.

Authors:  Teresa Barcina Lacosta; Arnold G Vulto; Adina Turcu-Stiolica; Isabelle Huys; Steven Simoens
Journal:  BioDrugs       Date:  2022-03-18       Impact factor: 7.744

7.  Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018.

Authors:  Yifei Liu; Martha Skup; Min Yang; Cynthia Z Qi; Eric Q Wu
Journal:  Adv Ther       Date:  2022-06-23       Impact factor: 4.070
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.